Product Description
Mechanisms of Action: TK Inhibitor,ERBB2 Inhibitor,EGFR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aslan
Company Location: SINGAPORE U0 239920
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Unknown Location
Active Clinical Trial Count: 1
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20171140 | P2 |
Active, not recruiting |
Unknown |
None |